Next-generation SERD camizestrant significantly reduces risk of disease progression in patients with advanced ER+ HER2- breast cancer

by VHIO

The phase II SERENA-2 randomized, multi-dose clinical trial compared the efficacy of next-generation SERD camizestrant (developed by AstraZeneca) with fulvestrant.

Read more

Next generation SERD camizestrant significantly improves progession-free survival vs fulvestran in advanced ER+ HER2- breast cancer

by VHIO

Findings show that camizestrant, an oral next generation selective estrogen receptor degrader (ngSERD), significantly improves progression-free survival versus fulvestrant in patients with estrogen re...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Some regions of the human genome conside...

by Universitat de Barcelona

Many repetitive regions of the genome have been considered “junk DNA...

Photos Stream